Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

BACKGROUND & AIMS The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study. METHODS In an observational longitudinal study, we began collecting data on eligible individuals with suspected DILI in 2004, following them for 6 months or longer. Subjects were evaluated systematically for other etiologies, causes, and severity of DILI. RESULTS Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 patients, and 899 were considered to have definite, highly likely, or probable DILI. Ten percent of patients died or underwent liver transplantation, and 17% had chronic liver injury. In the 89 patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those without (difference not statistically significant; P = .09) and mortality was significantly higher (16% vs 5.2%; P < .001). Azithromycin was the implicated agent in a higher proportion of patients with pre-existing liver disease compared with those without liver disease (6.7% vs 1.5%; P = .006). Forty-one cases with latency ≤7 days were caused predominantly by antimicrobial agents (71%). Two most common causes for 60 DILI cases with latency >365 days were nitrofurantoin (25%) or minocycline (17%). There were no differences in outcomes of patients with short vs long latency of DILI. Compared with individuals younger than 65 years, individuals 65 years or older (n = 149) were more likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ. Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin. Four of these patients died. CONCLUSIONS Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without. Additional studies are needed to confirm the association between azithromycin and increased DILI in patients with chronic liver disease. Older age and short or long latencies are not associated with DILI mortality.

[1]  N. Kaplowitz,et al.  Drug-induced liver injury. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Jiezhun Gu,et al.  Characteristics of Idiosyncratic Drug-induced Liver Injury in Children: Results From the DILIN Prospective Study , 2011, Journal of pediatric gastroenterology and nutrition.

[3]  J. Hoofnagle,et al.  Drug‐induced liver injury network (DILIN) , 2004, Hepatology.

[4]  R. Andrade,et al.  Phenotypic characterization of idiosyncratic drug‐induced liver injury: The influence of age and sex , 2009, Hepatology.

[5]  William M. Lee.  Drug-induced acute liver failure. , 2013, Clinics in liver disease.

[6]  William M. Lee,et al.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. , 2014, Gastroenterology.

[7]  Pradip Kumar Saha,et al.  Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. , 2002, American journal of respiratory and critical care medicine.

[8]  V. Navarro.  Liver injury due to herbal and dietary supplements , 2015 .

[9]  R. Schwartz,et al.  Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. , 2013, Journal of the American Academy of Dermatology.

[10]  William M. Lee,et al.  Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations , 2013, Hepatology.

[11]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[12]  Luis Rodrigo,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[13]  William M. Lee,et al.  ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury , 2014, The American Journal of Gastroenterology.

[14]  Jiezhun Gu,et al.  Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity , 2013, Digestive Diseases and Sciences.

[15]  A. Regev.  How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. , 2013, Clinics in liver disease.

[16]  H. Barnhart,et al.  Liver injury from herbals and dietary supplements in the U.S. Drug‐Induced Liver Injury Network , 2014, Hepatology.

[17]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[18]  H. Barnhart,et al.  Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis , 2012, Annals of Internal Medicine.

[19]  Dean P. Jones,et al.  Chapter 26 – Drug-Induced Liver Injury , 2006 .

[20]  H. Devarbhavi,et al.  Drug‐Induced liver injury with hypersensitivity features has a better outcome: A single‐center experience of 39 children and adolescents , 2011, Hepatology.

[21]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[22]  William M. Lee,et al.  ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury , 2014, The American Journal of Gastroenterology.

[23]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[24]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[25]  R. Fontana,et al.  Drug-induced Liver Injury Caused by Intravenously Administered Medications: The Drug-induced Liver Injury Network Experience , 2013, Journal of clinical gastroenterology.

[26]  K. Ishak,et al.  Isoniazid-associated hepatitis in 114 patients. , 1975, Gastroenterology.

[27]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[28]  D. Harnois.  Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .

[29]  R. Fontana,et al.  Duloxetine hepatotoxicity: a case‐series from the drug‐induced liver injury network , 2010, Alimentary pharmacology & therapeutics.

[30]  R. Fontana,et al.  Drug-Induced Liver Injury Network (DILIN) Prospective Study , 2009, Drug safety.

[31]  B. Stricker,et al.  Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases , 1988, Hepatology.

[32]  R. Andrade,et al.  Determinants of the clinical expression of amoxicillin‐clavulanate hepatotoxicity: A prospective series from Spain , 2006, Hepatology.

[33]  R. Schwartz,et al.  Toxic epidermal necrolysis , 2020, Definitions.

[34]  J. Koziol,et al.  Range of antinuclear antibodies in "healthy" individuals. , 1997, Arthritis and rheumatism.

[35]  Jiezhun Gu,et al.  Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. , 2011, Gastroenterology.

[36]  H. Conjeevaram,et al.  Clinical and histopathologic features of fluoroquinolone-induced liver injury. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.